Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aegera Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Aegera Therapeutics Inc. was formed in May 2000 through the merger of Apoptogen Inc. and Exogen Neurosciences Inc. Aegera will build on the neural signal transduction and apoptosis platforms of its founding companies with a goal of discovering and developing therapeutics for neurodegenerative diseases, peripheral neuropathies and cancer.

You may also be interested in...



New Approaches for Neurodegenerative Disorders

Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. The market for neuroscience therapies is currently the fastest growing segment in pharmaceuticals, and is projected to become the leading therapeutic area within five years. Small wonder that new companies are entering the fray, hoping to capture a share of this multi-billion dollar opportunity as well as to finally offer a cure to the victims of these diseases.

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)

In Vivo's Deals Of The Month, January 2018

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090284

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel